IMMUNOCLIN CORP COM USD0.001 (IMCL)

0.16
0.01 6.11
OTC
Prev Close 0.15
Open 0.16
Day Low/High 0.16 / 0.16
52 Wk Low/High 0.10 / 0.19
Volume 5.00K
Exchange OTC
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)

Latest News

Report: Eli Lilly Looks To Make More Deals

Report: Drugmaker Eli Lilly & Co. looks to acquire, but don't expect a mega-deal

Amylin Nominates 2 New Directors Amid Proxy Fight

Amylin Pharmaceuticals nominates 2 new directors as Icahn, others try to replace board members

Report: Swiss Drugmaker Nycomed Shopping Itself

Report: Nycomed, maker of Protonix, reportedly considering $13B sale

GenVec Stock Hit by Pancreas Study's Details

GenVec's shares sank Wednesday despite what the company said was a positive update on its experimental pancreatic cancer drug TNFerad.

Gimme Five

Five of my stocks are trading at good long-term valuations, and I'm going to be opportunistic here.

Adding on Weakness

With the Dow taking another tumble again, I am going to jump on the opportunity to add to some of my core holdings.

Health Winners & Losers: Eli Lilly

The company launches its bid to take over ImClone.

Eli Lilly Commences Tender Offer for ImClone

The $70-a-share offer represents a 51% premium to ImClone's closing stock price July 31, when a Bristol-Myers' offer came to light.

Eli Lilly's Lesson in Long-Term Thinking

Smaller companies could learn a lot from Big Pharma's constant focus on the future.

Health Winners & Losers: King Pharma

King Pharmaceuticals bucks an otherwise dismal day in health stocks.

Health Winners & Losers: Genentech

Genentech shares drop on investor concerns about financing for the company's deal with Roche but ease off their lows by the closing bell.

Dow Stages Recovery, but Falls Shy of 10,000

The Dow, which sank as much as 800 points earlier, stages a late-day rally to end the session down 3.6%. Frank Curzio breaks down the action in The Real Story video (above).

Stocks Pare Steepest Losses of the Day

The Dow, which sank as much as 800 points earlier, remains below 10,000, but has eased off its worst session lows.

Dow Dives 785 Points

The Dow sinks 7.6%, and the S&P and Nasdaq plummet more than 6% after fearful investors send stocks down around the world.

Health Winners & Losers: ImClone

Biotech stocks were falling along with the broader market Monday, but confirmation of Eli Lilly's bid lifted ImClone shares.

Dow Industrials Sink Below the 10,000 Mark

The Dow sinks 5%, and the S&P and Nasdaq plummet more than 6% after fearful investors send stocks down around the world.

Lilly to Buy ImClone for $6.5 Billion

The agreement, which values ImClone at $70 a share, has been approved by the boards of both ImClone and Eli Lilly.

Good Time for Dividend Stocks

Adding to some holdings with a good yield.

Dow Industrials Sink Below the 10,000 Mark

The Dow falls along with the other major indices on Wall Street Monday following dismal stock performances in Asia and Europe.

U.S. Stocks Sink at Open

Stocks in New York begin the week lower following dismal stock performances in Asia and Europe. The selloff has the Dow industrials back around the 10,000 level.

U.S. Stock Futures Point to Downside Open

The credit crisis had spread beyond America into Europe and Asia. Stocks fall hard overseas.

U.S. to Open Lower as Credit Crisis Spreads

The credit crisis had spread beyond America into Europe and Asia. Stocks fall hard overseas.

This Week on TheStreet.com TV

Biotech breakdown, TheStreet.com's new BlackBerry application, rebounding retail stocks, and much more.

Jim Cramer's 'Stop Trading!': Rate-Cut Bellwethers

These stocks wouldn't be going down if the Fed weren't going to do something, Cramer says.

Health Winners & Losers: ImClone

ImClone shares were trading up on continuing talks about its mystery suitor.

Dividend.com: Will Lilly Blossom?

The drug giant is reportedly the mystery suitor in talks to buy ImClone Systems.

Identity of ImClone Suitor Will Have to Wait

The Wall Street Journal reported Wednesday Eli Lilly offered $70 a share for ImClone, topping Bristol-Myers' $62-a-share bid.

Health Winners & Losers: ImClone

The company's shares rise as it awaits word from a mystery suitor about an offer.